ANNX — Annexon, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1528115 ·
Last close
$3.47
Market Cap
$661.95M
52W High
$7.18
52W Low
$2.99
ADV30
3,551,316
Next earnings
2026-11-11
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -52,238,000 -51,218,000 250,408,000 102,389,000 107,613,000
Jun 2026 0 — -57,227,000 -55,348,000 246,068,000 199,270,000 60,007,000
Mar 2026 0 — -46,053,000 -44,142,000 262,888,000 175,208,000 58,355,000
Dec 2025 0 — -50,258,000 -48,256,000 277,571,000 162,051,000 65,923,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-189,409,000
Investing CF
$-59,996,000
Financing CF
$212,374,000
CapEx
$-137,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,068,097,000
Inventory
—
Receivables
—
ST Investments
$110,985,000
EBIT TTM
$-203,923,000
Pretax Income TTM
$-198,964,000
Interest Exp TTM
$833,000
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -216,407,000 -206,690,000 277,571,000 65,923,000 211,648,000 -186,356,000
Dec 2024 0 -154,073,000 -138,200,000 350,071,000 56,966,000 293,105,000 -118,006,000
Dec 2023 0 -143,723,000 -134,237,000 297,674,000 47,118,000 250,556,000 -121,142,000
Dec 2022 0 -145,599,000 -141,947,000 285,096,000 53,902,000 231,194,000 -116,309,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-202,668,000
OpCashFlow TTM
—
Assets (Latest)
$246,068,000
Forward EPS
$-1.10

Max Pain — expiry 2026-12-18

max pain strike: $5.00 · spot: $3.52 · call oi: 21,257 · put oi: 6,908
Expected Move to 2026-12-18: ±$2.45 (69.60%) — implied range $1.07 – $5.97 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVCT Nuvectis Pharma, Inc. $660.27M $19.20 —
JANX Janux Therapeutics, Inc. $655.27M $10.71 —
GERN GERON CORP $644.24M $1.00 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —

News headlines (Yahoo Finance, 1h cache)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-11-17 21:01 · Yahoo
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
2026-11-09 21:01 · Yahoo
Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug
2026-11-04 10:14 · Yahoo
Annexon to Participate in Upcoming September Investor Conferences
2026-09-02 12:00 · Yahoo
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
2026-08-24 08:08 · Yahoo
Annexon (ANNX), What Is Behind Its Latest Update?
2026-08-13 18:13 · Yahoo
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
2026-08-12 11:33 · Yahoo
Wells Fargo Names Top Pick in Biotechnology Sector
2026-11-11 16:24 · Yahoo
Annexon, Inc. Q2 2026 Earnings Call Summary
2026-08-12 20:56 · Yahoo
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
2026-10-28 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.